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colleagues also provide evidence that
the N-terminal portion of Tmem27 can
be cleaved and shed from b cells. How-
ever, this shed fragment showed no bio-
logical activity, and the authors conclude
that the full-length version of Tmem27
is responsible for cellular proliferation
through either a cell-autonomous or cell-
cell-signaling effect.
The divergent conclusions drawn on
the function of Tmem27 by the two labo-
ratories are difficult to reconcile at pres-
ent. This is true especially for the obser-
vations made on the transgenic mouse
models, which in both cases utilize the
rat insulin promoter to direct overexpres-
sion of Tmem27 to the pancreatic b cell.
One possibility for the different pheno-
types of the two mouse models is
the level of overexpression achieved,
which is two- versus 4-fold. Another
possibility to consider is that of trans-
gene integration site effects. During the
establishment of a transgenic mouse
line, the transgene integrates, often as
a concatamer of multiple copies, ran-
domly into the genome. On a rare occa-
sion, this integration disrupts the function
of another gene, causing a phenotype.
Finally, strain differences can also affect
the outcome of transgenic mouse experi-
ments. Clearly, a lot more work is re-
quired to reconcile these differences
and to establish which mechanism of ac-
tion of Tmem27 is the predominant one.
In summary, it is clear that Tmem27
is a novel and direct target of the
MODY3 gene HNF-1a in pancreatic
b cells, which has dramatic effects on
b cell function. The final evaluation of its
molecular mechanism of action will re-
quire studies in mice with targeted abla-
tion of this gene. Regardless of the con-
troversy surrounding the function of
Tmem27, it is an exciting potential phar-
macological target for the treatment of
type 2 diabetes.
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P R E V I E W SOsteoprotegerin, the bone protector, is a
surprising target for b-catenin signaling
Osteoblasts influence bone mass by the amount of bone they synthesize and by regulating osteoclasts, the cells that de-
grade bone. In the December issue of Developmental Cell, Kieslinger et al. (2005) show that immature osteoblasts regulate
expression of the osteoclast inhibitor, osteoprotegerin, through an early B cell factor and b-catenin signaling.As baby boomers age, they face many
challenges: increasing health insurance
costs, diabetes, the metabolic syn-
drome, Alzheimer’s, and the increasing
risk of fracture because of thinning
bones. Congress, recognizing the need
to investigate the molecular mechanisms
regulating the function of bone cells, de-
clared a decade of bone and joint re-
search starting in 2002. This has yielded
enormous success, with major advances
in the understanding of how the skeleton
and bone cells are formed and how bone
is remodeled (renewed) in adult life. This
is exemplified by findings reported earlier
this year indicating that Wnt signaling not
only determines if mesenchymal progen-344itors will become chondrocytes or osteo-
blasts (Hill et al., 2005) but also regulates
bone mass through osteoblastic control
of bone resorption. Bone is remodeled
throughout life. Pockets or trenches of
worn out bone are removed during re-
modeling by osteoclasts, which dig re-
sorption trenches on bone surfaces. Ma-
ture osteoblasts fill in the trenches with
new stronger bone, in much the same
way as workmen repair roadways. Bone
mass, strength, and fracture risk are de-
termined by many factors, including the
amount of matrix laid down by osteo-
blasts and removed by osteoclasts.
Somewhat surprisingly, the osteoblast
appears to be the foreman controllingbone remodeling. Osteoblasts orches-
trate bone destruction by expressing Re-
ceptor Activator of NF-kB (RANK) ligand
in response to osteoclast-stimulating
hormones and cytokines, such as PTH,
TNF, and IL-1, but they also protect the
skeleton by secreting osteoprotegerin
(OPG) (Simonet et al., 1997). RANKL
binds to its receptor, RANK, on osteo-
clast precursors to mediate osteoclast
differentiation and subsequent activa-
tion; osteoprotegerin, a secreted nonsig-
naling decoy receptor for RANKL, inhibits
both physiological and pathological bone
resorption. Surprisingly, Opg expression
was found to be regulated by b-catenin
signaling through TCF1 (Glass et al.,CELL METABOLISM : DECEMBER 2005
P R E V I E W S2005). In the current issue of Develop-
mental Cell, Kieslinger et al. (2005) con-
firm this role for b-catenin by showing
that earlyB cell factor 2 (EBF2), amember
of the early B cell factor family, regulates
Opg expression in synergy with LEF1,
another transcription factor mediating
b-catenin function.
Wnt proteins play critical roles in carci-
nogenesis and in early development,
controlling mesoderm induction, pattern-
ing, cell-fate determination, morphogen-
esis, and bone development (reviewed
by Huelsken and Birchmeier, 2001).
Wnts form a dual-receptor complex
with Frizzled and low-density-lipoprotein
(LDL)-receptor like protein 5 or 6 (LRP5/6)
on cell surfaces. This triggers signaling
through a large protein complex in the
Wnt canonical pathway, including glyco-
gen synthase kinase 3b (GSK-3b), casein
kinase I, and the scaffolding proteins, ad-
enomatous polyposis coli (APC), dishev-
elled, and axin. This complex has multi-
ple effects on b-catenin: for example, it
promotes b-catenin phosphorylation by
GSK-3b, enabling it to be detected and
destroyed by the proteasome. However,
the N-terminal domain of LRP5 mediates
its interaction with theWnt-frizzled ligand-
receptor complex, and the intracellular
tail of LRP5/6 binds axin, which inhibits
b-catenin phosphorylation by GSK-3b al-
lowing b-catenin to move to the nucleus.
Nuclear b-catenin combines with the
transcription factors TCFs and LEF1 to
activate expression of target genes.
Recent studies of mutations in humans
have demonstrated that Wnts and pro-
teins associated withWnt signaling regu-
late bone mass. For example, patients
with osteoporosis pseudoglioma syn-
drome, an autosomal recessive disorder
mapped to a locus at chromosome
11q12-13, have normal bone growth
but severe osteoporosis due to inactivat-
ing mutations of LRP5. Lrp5-deficient
mice have a similar phenotype due to de-
creased bone formation. Interestingly,
high bone mass (HBM) syndrome also
has been mapped to this chromosomal
region and is due to an activating muta-
tion (Gly171Val) in Lrp5. These studies
spurred a genetic approach in mice to
study the role of b-catenin signaling in
osteoblastic bone formation. Osteoblast-
specific activation of the b-catenin gene
using a1(1) collagen-Cre in mice resulted
in high bone mass, while deletion of
b-catenin in osteoblasts led to osteo-
penia (Glass et al., 2005). BecauseCELL METABOLISM : DECEMBER 2005LRP5 regulates osteoblast function and
b-catenin expression is required for the
differentiation of mesenchymal progeni-
tors into osteoblasts, it was anticipated
that the major role for b-catenin in osteo-
blasts would be regulation of their for-
mation and function. Surprisingly, the
changes in bone mass in the above
b-cateninmutant mice are due to defects
in osteoclast-mediated bone resorption,
and Opg turns out to be a direct target
gene for b-catenin in vitro (Jackson
et al., 2005) and in vivo (Glass et al.,
2005). Furthermore, conditional deletion
of the Apc gene in mature osteoblasts
by osteocalcin-Cre results in constitutive
activation of b-catenin, increased bone
deposition, and the absence of osteo-
clasts (Holmen et al., 2005). These mice
have increased levels of serum OPG
and their osteoblasts display decreased
Rankl expression. More dramatically, the
conditional deletion of b-catenin in ma-
ture osteoblasts by the same osteocal-
cin-Cre system leads to osteoporosis,
decreased Opg, and increased Rankl
expression (Holmen et al., 2005). Now,
Kieslinger et al. (2005) report that the
EBF family member, EBF2, activates
Opg gene transcription in a synergistic
manner with the Wnt/b-catenin signaling
transcription factor, LEF1, in immature
osteoblasts that do not express osteo-
calcin and thus inhibits osteoclast forma-
tion. Consequently, Ebf22/2 mice have
reduced bone mass and increased num-
bers of osteoclasts. Their bone formation
rate is normal and their osteoblasts ex-
press decreased Opg and increased
Rankl. These authors showed that Opg,
but not Rankl, is a target for EBF2.
These new studies suggest that both
mature and immature osteoblasts can
regulate Opg expression in a b-catenin-
dependent manner. There are many
types of cells in the osteoblast lineage,
including progenitors, regulators of he-
matopoiesis and resorption, matrix se-
cretors, osteocytes, and bone surface
lining cells. Kieslinger et al. suggest that
immature osteoblasts, which express
low levels of alkaline phosphatase and
type I collagen and do not express os-
terix and osteocalcin regulate Opg ex-
pression, but the Glass and Holmen pa-
pers indicate that this is done by more
mature osteoblasts which express type
I collagen and osteocalcin, respectively,
i.e., cells with the capacity to lay down
bone matrix. It is not easy to explain
these discrepant findings. Intuitively,one would predict that a mature osteo-
blast busy building bone away from sites
where bone is being removed would
keep osteoclasts away by secreting
OPG and that more immature cells would
regulate resorption by expressing
RANKL and little OPG. It is not clear if
Wnt/b-catenin signaling also regulates
transcription of Rankl. In osteoblasts in
which the b-catenin gene is specifically
deleted by Col1a1-Cre,Rankl expression
is normal (Glass et al., 2005), while in
more mature osteoblasts in which the
b-catenin gene is specifically deleted by
osteocalcin-Cre, Rankl levels are signifi-
cantly increased (Holmen et al., 2005), al-
thoughOpg expression is similar in these
two osteoblast-specific b-catenin mu-
tants. Is the discrepancy in Rankl expres-
sion due to differences in the differenti-
ated state of osteoblasts? We will also
need to find out which cells regulate os-
teoblasts in these processes, andwhether
the osteoblasts are immature or more
mature cells.
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